Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer with Homologous Recombination Deficiency (PreCISeRT)

NCT05182112 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05182112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05182112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer with Homologous Recombination Deficiency (PreCISeRT)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
December 20, 2021
Completion date
November 4, 2024
Enrollment
1 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer